Integrated Wealth Concepts LLC reduced its stake in DuPont by 65.3% in Q2, selling over 13,000 shares. This divestment occurred despite the company reporting strong quarterly earnings. Institutional ownership remains robust at nearly 74%, indicating sustained broad interest. Analyst consensus maintains a Moderate Buy rating with a price target of $166.60. DuPont beat EPS expectations and saw a 4% revenue increase, contrasting with the significant shareholder reduction. The sale likely reflects portfolio rebalancing rather than fundamental weakness.
88 articles
Integrated Wealth Concepts LLC reduced its DuPont de Nemours stake by 65.3% in Q2, selling 13,713 shares. DuPont reported strong Q2 earnings beating EPS expectations with a 4% revenue increase.
Chemours, DuPont, and Corteva agreed to a $455 million settlement with North Carolina over PFAS litigation at the Fayetteville Works facility. Chemours will bear 50% of the cost, paid over 15 years, a
Tidal Investments LLC reduced its stake in DuPont de Nemours by selling 53,359 shares. DuPont exceeded quarterly earnings expectations with $1.88 EPS, maintaining a Moderate Buy rating.
HB Wealth Management LLC reduced its DuPont de Nemours stake by 70.1% in Q2. The chemical firm reported strong earnings but cut dividends while other institutions increased holdings.
Baird Financial Group Inc. reduced its DuPont de Nemours stake by 66.3% in Q2, selling 187,448 shares. DuPont recently beat EPS estimates, maintaining a Moderate Buy rating from analysts despite the i
Arizona State Retirement System reduced its DuPont de Nemours stake by 65.6% in Q2, retaining $5.31 million. Meanwhile, DuPont reported strong quarterly earnings beating estimates with analysts mainta
Corteva, DuPont, and Chemours agreed to a $455 million settlement with North Carolina over PFAS contamination claims at the Fayetteville Works site. Corteva's portion is approximately $66 million, alo
KeyBanc initiated Corteva stock at Sector Weight, highlighting spin-off concerns and a $455 million PFAS settlement despite recognizing strong fundamentals.
Empirical Finance LLC reduced its stake in DuPont de Nemours by 65.7% in Q2, selling 10,483 shares. Meanwhile, DuPont reported strong Q2 earnings exceeding analyst estimates with a maintained Moderate
Qnity Electronics retains a $43 million indemnity liability linked to DuPont's North Carolina PFAS settlement per SEC filings. Despite covering 44% of DuPont's after-tax responsibility, Qnity reports
Chemours, DuPont, and Corteva agreed to a $455 million settlement over 15 years to resolve PFAS-related claims in North Carolina, with Chemours covering 50% of payments while allowing continued operat
Wellington Management Group LLP reduced its stake in DuPont de Nemours by 64.2%, selling 59,724 shares in Q2. DuPont also reported strong quarterly earnings, beating expectations with $1.88 EPS and de
Concurrent Investment Advisors LLC reduced its stake in DuPont de Nemours by 62.8% in Q2, while the company posted stronger-than-expected earnings and declared a $0.60 dividend.
TD Waterhouse Canada Inc. reduced its DuPont stake by 87.2% to $1.67 million in Q2. DuPont reported strong quarterly earnings beating estimates, with analysts maintaining a Moderate Buy rating.
Community Bank N.A. reduced its DuPont de Nemours stake by 67.2% in Q2, while other institutions increased holdings. The company beat earnings estimates with a Moderate Buy consensus and $166.60 targe
Mraz Amerine & Associates Inc. reduced its DuPont stake by 66.5% in Q2, while DuPont reported strong Q2 earnings with $1.88 adjusted EPS.
Greenleaf Trust reduced its DuPont de Nemours stake by 71.8% in Q2, selling 14,453 shares. DuPont also reported strong Q2 earnings with $1.88 EPS and announced a $0.60 quarterly dividend.
Addenda Capital Inc. reduced its stake in DuPont de Nemours by 66.7% in Q2, while the company beat earnings forecasts and declared a $0.60 quarterly dividend.
DuPont de Nemours Inc. shares fell 1.20% to close at $136.67 on Monday, marking three consecutive days of losses during a mixed trading session.
DuPont de Nemours Inc. reports a forward price-to-sales ratio on the BCBA exchange, with the market closed and no trades recorded at publication.
TradingView displays the forward price-to-sales ratio for DuPont de Nemours Inc., noting the market was closed with no trades reported at publication.
Simply Wall St analyzes DuPont de Nemours, highlighting valuation and growth prospects alongside new direct lithium extraction products and PFAS legal updates.
DuPont de Nemours stock outperformed the S&P 500 driven by growth in water treatment and biopharma processing. Analysts maintain a Strong Buy rating with significant upside potential.
RBC Capital lowered DuPont de Nemours' price target to $176 while maintaining an Outperform rating after Q2 2026 earnings showed revenue and earnings growth with updated guidance.
UBS raised its price target for DuPont de Nemours to $178 and maintained a Buy rating following strong second-quarter 2026 earnings and a raised full-year profit outlook.
DuPont reported better-than-expected Q2 2026 results with raised full-year guidance while actively exploring M&A opportunities in water and healthcare sectors. Additionally, the company announced plan
DuPont raised its annual profit forecast after exceeding second-quarter estimates, driven by price hikes and strategic cost cuts. The company successfully countered rising feedstock and energy costs a
DuPont de Nemours Inc shares rose 3.1% to $141.28, yet GuruFocus values indicate significant overvaluation with a forward P/E of 19.8x versus a 5-year median of 6.6x.
Lombard Odier Asset Management Europe Ltd reduced its stake in Corteva by 11.9% in Q1 2026, selling 22,426 shares. The adjustment occurs despite Corteva raising its fiscal 2026 EPS outlook following a
Analysts recommend a "Buy" trend for DuPont de Nemours Inc (DD) with an average price target of $46.12. The company expects next quarter revenue of $1.81 billion and EPS of $1.77.
ChemBrief